Your search history is turned on.
Date: April 29, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Algernon Pharmaceuticals Inc. February 29, 2024 MD&A Algernon Pharmaceuticals Inc. MANAGEMENTS DISCUSSION AND ANALYSIS For the six months ended February 29, 2024 Dated April 29, 2024 Prepared by Management without review by the Companys auditor ALG...
Algernon - Financial Statements - February 29, 2024 - FINAL ALGERNON PHARMACEUTICALS INC. Condensed Interim Consolidated Financial Statements (Unaudited) For the six months ended February 29, 2024 and February 28, 2023 (Expressed in Canadian dollars) In accordance wi...
Microsoft Word - CFO Certification Q3 2021 FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, James Kinley, Chief Financial Officer of Algernon Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Algernon Pharmaceuticals Inc. (...
Microsoft Word - CEO Certification Q3 2021 FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Christopher Moreau, Chief Executive Officer of Algernon Pharmaceuticals Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Algernon Pharmaceuticals...
Date: April 26, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Shareholder Meeting Checklist - BOS VERSION JAN 11 2024.xlsm VIA ELECTRONIC TRANSMISSION TO ALL APPLICABLE EXCHANGES AND COMMISSIONS: RE: ALGERNON PHARMACEUTICALS INC. Confirmation of Notice of Record and Meeting Dates We are pleased to confirm that Notice of Record and Meeting Dates was sent to The Canadian Depository for Securities. We advise the following wit...
Date: April 24, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 8th, 2024 April 24, 2024 Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 8th, 2024 VANCOUVER, Britis...
Date: April 11, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024 April 11, 2024 Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024 VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceutical...
Date: April 10, 2024 Jurisdictions: British Columbia
Create report of exempt distribution (Form 45-106F1) Form 45-106F1 Report of Exempt Distribution ITEM 1 - REPORT TYPE New report Amended report If amended, provide filing date of report that is being amended. (YYYY-MM-DD) ITEM 2 - PARTY CERTIFYING THE REPORT Indicate the party certifying the report (select only one). For guidance regarding whether an ...
Date: April 2, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset April 1, 2024 Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the Company or Algernon) (CSE: AGN) (FRANKFURT: AGW...
Date: March 27, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
AGN - material change report - March 27, 2024 Form 51102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Algernon Pharmaceuticals Inc. (AGN or the Company) Suite 400 601 West Broadway Vancouver, British Columbia V5Z 4C2 Item 2. Date of Material Change March 27, 2024 Item 3. News Release News Release dated March 27, 2024 was...